vs
Side-by-side financial comparison of AVALON HOLDINGS CORP (AWX) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
AVALON HOLDINGS CORP is the larger business by last-quarter revenue ($21.5M vs $18.6M, roughly 1.2× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -1.7%, a 67.4% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 21.7%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 6.7%).
Avalon Hill Games Inc. is a game company that publishes wargames and strategic board games. It has also published miniature wargaming rules, role-playing games and sports simulations. It is a subsidiary of Hasbro, and operates under the company's "Hasbro Gaming" division.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
AWX vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.5M | $18.6M |
| Net Profit | $-356.0K | $12.3M |
| Gross Margin | 17.1% | — |
| Operating Margin | 0.4% | 56.3% |
| Net Margin | -1.7% | 65.7% |
| Revenue YoY | 21.7% | 1808.5% |
| Net Profit YoY | 28.4% | 376.5% |
| EPS (diluted) | — | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.5M | $18.6M | ||
| Q3 25 | $25.7M | $334.0K | ||
| Q2 25 | $20.3M | $1.4M | ||
| Q1 25 | $16.1M | $257.0K | ||
| Q4 24 | $17.6M | $977.0K | ||
| Q3 24 | $24.2M | $660.0K | ||
| Q2 24 | $23.1M | $736.0K | ||
| Q1 24 | $18.9M | $1.4M |
| Q4 25 | $-356.0K | $12.3M | ||
| Q3 25 | $1.9M | $-8.6M | ||
| Q2 25 | $274.0K | $-6.9M | ||
| Q1 25 | $-1.5M | $-5.4M | ||
| Q4 24 | $-497.0K | — | ||
| Q3 24 | $1.8M | $-2.8M | ||
| Q2 24 | $954.0K | $-14.5M | ||
| Q1 24 | $-979.0K | $411.0K |
| Q4 25 | 17.1% | — | ||
| Q3 25 | 23.7% | — | ||
| Q2 25 | 20.6% | — | ||
| Q1 25 | 14.8% | — | ||
| Q4 24 | 17.5% | — | ||
| Q3 24 | 24.6% | — | ||
| Q2 24 | 22.1% | — | ||
| Q1 24 | 16.2% | — |
| Q4 25 | 0.4% | 56.3% | ||
| Q3 25 | 9.1% | -2516.5% | ||
| Q2 25 | 3.7% | -701.0% | ||
| Q1 25 | -7.2% | -3350.2% | ||
| Q4 24 | -0.8% | — | ||
| Q3 24 | 9.4% | -1563.6% | ||
| Q2 24 | 6.3% | -1255.0% | ||
| Q1 24 | -2.7% | -692.5% |
| Q4 25 | -1.7% | 65.7% | ||
| Q3 25 | 7.4% | -2572.2% | ||
| Q2 25 | 1.4% | -504.8% | ||
| Q1 25 | -9.3% | -2097.7% | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | 7.6% | -425.5% | ||
| Q2 24 | 4.1% | -1964.4% | ||
| Q1 24 | -5.2% | 29.9% |
| Q4 25 | — | $0.25 | ||
| Q3 25 | — | $-0.17 | ||
| Q2 25 | — | $-0.14 | ||
| Q1 25 | — | $-0.11 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | — | $-0.30 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.1M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $38.4M | $49.4M |
| Total Assets | $87.4M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.1M | $40.0M | ||
| Q3 25 | $4.6M | $37.9M | ||
| Q2 25 | $3.7M | $44.8M | ||
| Q1 25 | $1.3M | $40.6M | ||
| Q4 24 | $2.8M | $59.3M | ||
| Q3 24 | $3.9M | $68.8M | ||
| Q2 24 | $3.8M | $73.0M | ||
| Q1 24 | $1.2M | $80.2M |
| Q4 25 | $38.4M | $49.4M | ||
| Q3 25 | $38.7M | $36.4M | ||
| Q2 25 | $36.8M | $44.5M | ||
| Q1 25 | $36.5M | $50.5M | ||
| Q4 24 | $38.0M | $55.1M | ||
| Q3 24 | $38.5M | $58.5M | ||
| Q2 24 | $36.7M | $60.4M | ||
| Q1 24 | $35.7M | $74.1M |
| Q4 25 | $87.4M | $59.0M | ||
| Q3 25 | $90.7M | $51.1M | ||
| Q2 25 | $88.1M | $60.7M | ||
| Q1 25 | $87.6M | $67.9M | ||
| Q4 24 | $86.2M | $90.6M | ||
| Q3 24 | $89.1M | $99.0M | ||
| Q2 24 | $91.7M | $107.8M | ||
| Q1 24 | $90.6M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $278.0K | $18.4M |
| Free Cash FlowOCF − Capex | $-166.0K | — |
| FCF MarginFCF / Revenue | -0.8% | — |
| Capex IntensityCapex / Revenue | 2.1% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $2.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $278.0K | $18.4M | ||
| Q3 25 | $1.5M | $-8.7M | ||
| Q2 25 | $3.0M | $-7.5M | ||
| Q1 25 | $-982.0K | $-7.5M | ||
| Q4 24 | $-579.0K | $-24.0M | ||
| Q3 24 | $342.0K | $765.0K | ||
| Q2 24 | $3.2M | $-10.9M | ||
| Q1 24 | $411.0K | $-4.0M |
| Q4 25 | $-166.0K | — | ||
| Q3 25 | $852.0K | — | ||
| Q2 25 | $2.7M | — | ||
| Q1 25 | $-1.4M | — | ||
| Q4 24 | $-1.1M | — | ||
| Q3 24 | $-660.0K | — | ||
| Q2 24 | $2.9M | — | ||
| Q1 24 | $56.0K | — |
| Q4 25 | -0.8% | — | ||
| Q3 25 | 3.3% | — | ||
| Q2 25 | 13.5% | — | ||
| Q1 25 | -8.5% | — | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -2.7% | — | ||
| Q2 24 | 12.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 2.1% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 4.1% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 1.9% | — |
| Q4 25 | — | 1.50× | ||
| Q3 25 | 0.76× | — | ||
| Q2 25 | 11.07× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.19× | — | ||
| Q2 24 | 3.35× | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AWX
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
